What Inmunotek does

Inmunotek, S.L. is a privately held Spanish pharmaceutical laboratory founded in 1992 and headquartered in Alcalá de Henares, Madrid, with additional manufacturing facilities in San Sebastián de los Reyes and a wholly-owned Greek subsidiary, Inmunotek Hellas, in Athens. The company specializes in the research, development, manufacture, and commercialization of medicines and medical devices for the diagnosis and treatment of allergy and immunology conditions in both human and veterinary pathology. Its core product lines include allergen extracts for in-vivo skin prick diagnosis, allergen immunotherapy vaccines (anti-allergic vaccines), bacterial vaccines and autovaccines, the proprietary Prick-Film system for automated skin allergy testing, and the RhinoDouche family of nasal irrigation devices and saline formulations. All products are manufactured in-house under Good Manufacturing Practice (GMP) standards and are authorized by the Spanish Medicines Agency, with production supported by company-owned laboratories that produce biological raw materials (bacteria, fungi, mites), enabling vertical integration from raw material to finished dosage form.

The company's commercial model is a sales-led B2B motion targeting licensed healthcare professionals (allergists, immunologists, and physicians) through a gated registration portal, direct medical visits, scientific congress participation, and a multilingual website available in Spanish, English, Greek, Portuguese, and German. Products are prescription-based medications and medical devices, with no direct-to-consumer dispensing model, and revenue is generated through one-time sales of allergen extracts, vaccines, and devices to professional customers. Distribution is hybrid: direct in Spain and Greece via the wholly-owned subsidiary, and through a network of third-party distributors across more than 50 countries on all continents. The company operates with a headcount of 51-100 employees, holds no disclosed external funding, and is led by founder Jose Luis Subiza as Founder & CEO, with Mónica Subiza Domínguez serving as Product Manager. In 2026, Inmunotek received the ASPID 2026 award in Madrid and exhibited at the EAACI 2026 European Academy of Allergy and Clinical Immunology congress, both indicative of continued commercial and scientific activity rather than a transformational shift in scale or direction.

Name

Inmunotek

Legal name

INMUNOTEK, S.L.

Website

https://inmunotek.com

Company type

Private

Founded year

1992

Operating status

Operating

Headcount range

51–100 employees

Short description

Inmunotek, S.L. is a privately held Spanish pharmaceutical laboratory, founded in 1992 and based in Alcalá de Henares, Madrid, that develops, manufactures, and commercializes allergen extracts, immunotherapy vaccines, bacterial autovaccines, and nasal irrigation devices under GMP standards for healthcare professionals across Spain and more than 50 countries.

Ownership category

akta.pro rank

Product category

Allergy and Immunology Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF)

akta.pro secondary industries

Allergy Immunotherapy Biologics (allergen extracts, desensitization) (HLAAAEAI), Respiratory & Allergy Pharmaceuticals (HLAIAAAH), Autoimmune & Allergy Diagnostics (HLAAALAK), Dermatology & Allergy Drugs (HLAMAEAH)

Keywords

• Allergen extract manufacturing
• Allergy immunotherapy vaccines
• Allergen diagnostic devices
• Nasal irrigation products
• Bacterial immunotherapy autovaccines

Headquarters

HQ city

Alcalá De Henares

HQ country

Spain

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Allergen Extracts and Vaccines: Manufacture and commercialization of allergen extracts for immunotherapy vaccines (antiallergic vaccines) and bacterial vaccines and mucosal immunotherapies, sold as prescription medicines. Revenue is generated through product sales to healthcare providers and institutions.
2. Diagnostic Extracts: Production and sale of a wide range of allergen extracts for in vivo allergy diagnosis (prick test) for respiratory and food allergies, as well as diagnostic devices such as Prick-Film and RhinoDouche.
3. Medical Devices / Health Products: Commercialization of health products including nasal irrigation devices (RhinoDouche, RhinoDouche Junior) and saline formulations (RhinoDouche Sal).

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Inmunotek researches, develops, manufactures, and commercializes prescription medicines and medical devices for allergy diagnosis and immunotherapy, along with nasal irrigation products. Its portfolio spans allergen extracts for skin prick testing, anti-allergic therapeutic vaccines, bacterial vaccines and autovaccines, the proprietary Prick-Film diagnostic system, and the RhinoDouche nasal irrigation device line, all manufactured under GMP standards and authorized by the Spanish Medicines Agency.

Product overview

Inmunotek is a pharmaceutical laboratory specializing in the manufacture and commercialization of products (medicines and medical devices) for allergy and immunology in both human and veterinary pathology. The product portfolio includes allergen extracts for diagnosis (Prick Test), anti-allergic therapeutic vaccines for immunotherapy, bacterial vaccines and autovaccines for immunotherapy, the Prick-Film diagnostic device system, and the RhinoDouche nasal irrigation product line including devices and saline formulations. Products are manufactured under Good Manufacturing Practice (GMP) standards and are authorized by the Spanish Drug Agency, commercialized in Spain and over 50 countries.

Differentiator

Problem solved

Functional benefit

Brands

• Prick-Film®: A system designed to facilitate the performance, reading, and archiving of skin allergy tests through automatic processing.
• RhinoDouche®

Products and services

• Allergen Extracts (Prick Test) Allergen extracts used by allergists and clinical immunologists for in vivo diagnosis of respiratory and food allergies through skin prick testing.
• Anti-Allergic Vaccines Prescription therapeutic vaccines for allergen immunotherapy used to treat allergic diseases, manufactured under GMP standards for healthcare professionals and patients under medical supervision.
• Bacterial Vaccines and Immunotherapy (Autovaccines) Autovaccines prepared from patient biological samples and bacterial vaccines designed to stimulate and improve the immune response against infectious microorganisms, used by physicians for bacterial immunotherapy.
• Prick-Film System Proprietary medical device that automates the performance, reading, and archiving of skin allergy tests, enabling rapid and clean cutaneous testing for allergists and immunologists.
• RhinoDouche Nasal irrigation medical device that cleans the nasal cavities and paranasal sinuses, sold to healthcare professionals and patients for nasal hygiene and respiratory symptom relief.
• RhinoDouche Junior Child-adapted nasal irrigation device with a smaller volume for nasal washes in pediatric patients, distributed alongside the adult RhinoDouche device.
• RhinoDouche Sal XL Saline formulation specifically developed for use with the RhinoDouche adult nasal irrigation device to enable nasal and sinus washes.
• RhinoDouche Sal Junior Pediatric saline formulation developed for use with the RhinoDouche Junior nasal irrigation device to enable nasal washes in children.

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• ALK-Abelló: Global leader in allergy immunotherapy with both SCIT and SLIT products across respiratory allergies. Directly competes with Inmunotek in prescription allergen vaccines and diagnostics, with substantially larger scale and pipeline.
• LETI Pharma: Spanish-based specialty pharmaceutical laboratory focused on allergy and immunology products. Operates as a direct domestic competitor to Inmunotek with overlapping allergen extract and immunotherapy vaccine offerings.
• HAL Allergy: European allergen immunotherapy company producing diagnostic and therapeutic allergen products. Closely comparable to Inmunotek's allergen extract, prick test, and immunotherapy vaccine portfolio.
• Allergy Therapeutics: UK-based specialty pharmaceutical company developing and commercializing allergy immunotherapy vaccines and diagnostics. Directly comparable to Inmunotek in allergen-specific immunotherapy, with a focus on both SCIT and novel approaches.
• Stallergenes Greer: Specialty biopharmaceutical company focused on allergen immunotherapy diagnosis and treatment. Competes head-to-head with Inmunotek in the prescription allergy vaccine and allergen extract markets globally.

Emerging players

• Biomay: Austrian biotech developing recombinant allergen-based immunotherapies. Comparable to Inmunotek's allergen focus but represents a next-generation, recombinant approach versus Inmunotek's traditional extract-based portfolio.

Broad incumbents

• Bayer: Global healthcare conglomerate with consumer health and pharmaceutical offerings touching allergy, sinus, and respiratory care. Adjacent competitor to Inmunotek's prescription allergy and OTC nasal irrigation products within a much broader portfolio.
• Sanofi: Global pharmaceutical major with allergy and respiratory franchises. Overlaps with Inmunotek in allergy/respiratory therapeutics at the portfolio level but competes as a broad incumbent rather than a specialized niche player.

Others

• Zendal Group: Spanish biotech group encompassing veterinary and human health divisions including allergy/immunology through LETI. Comparable as a Spanish-language ecosystem participant and parent of a direct competitor; relevant for understanding the local competitive cluster around Inmunotek.

Regional players

• Roxall Medizin: German specialty pharmaceutical company focused on allergen diagnostics and immunotherapy. Comparable to Inmunotek in product type but primarily serves German-speaking and Central European markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/inmunotek
• YouTubeyoutube.com/channel/UCBXBpI9LdloIB0pwKOome3A
• Facebookfacebook.com/Inmunotek
• LinkedInes.linkedin.com/company/inmunotek
• Instagraminstagram.com/inmunotek

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Inmunotek